BioNTech Collaborates with OncoC4 to Co-Develop CTLA-4 Cancer Antibody
By Ayush Saxena
Pharma Deals Review: Vol 2023 Issue 3 (Table of Contents)
Published: 24 Mar-2023
DOI: 10.3833/pdr.v2023.i3.2773 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to expand its oncology portfolio, BioNTech has entered into a global licensing and collaboration agreement with OncoC4 to co-develop and commercialise a clinical stage candidate, ONC-392, as a monotherapy or combination therapy in multiple tumour indications...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS